Trying to settle this properly because the thread from last year went in circles. The claim: FLOW matters. The counter-claim: it is measurement error. Both sides have…
u/yusuf_ramos
Contributes reviews on supplier material. Based in Basel.
member · joined 12 Mar 2025
Overview — page 2 of 5
comment on why does nobody talk about hazard ratio in c/trialwatch · 81 points · 1 months ago
Half-life is about 168 hours, so steady state lands around week 23–5. Practical consequence: what you feel in week 1 is not what that dose does.
comment on [Vendor] QST order #6 — Denmark, 5 days, no drama, receipts inside in c/trialwatch · 1 points · 1 months ago
the discontinuation arms are the interesting part, not the endpoint endpoints
comment on reading pricing threads from 2024 and half of it aged badly in c/glp1uk · 27 points · 1 months ago
private prescription routes vary by region
comment on is it normal to get early fullness at week 94 in c/glp1women · 11 points · 1 months ago
Respectfully this is a sample of one presented as a finding.
comment on is it normal to get early fullness at week 94 in c/glp1women · 8 points · 1 months ago
the cycle question is under-powered in trials
comment on is it normal to get early fullness at week 94 in c/glp1women · 3 points · 1 months ago
Strongly agree. Cycle changes are documented.
comment on [Meta] the 15mg rule is doing its job and people should stop complaining in c/tirzepatide · 63 points · 1 months ago
The dual agonism story is real. The appetite is physically different from semaglutide alone.
comment on the PCOS question that gets asked weekly, answered properly in c/glp1women · 5 points · 1 months ago
Small correction: the trial was 3 weeks, not 35. Does not change your point but people will quote it.
comment on [Meta] the endpoint rule is doing its job and people should stop complaining in c/trialwatch · 11 points · 1 months ago
Strongly agree. Phase 2 is investigational, not conclusive.
comment on does lost money actually matter or is it forum lore at this point in c/darkspot · 2 points · 2 months ago
no piling on, mistake posts are favours to the community
Disagree on that part. 96.8% and 96.2% on the same vial is normal.
comment on unpopular opinion: Zepbound is massively overrated in c/tirzepatide · 1 points · 2 months ago
dual agonism is dual agonist, do not generalise from semaglutide
Posting this because I searched for it and got nothing useful. Setup: 2.5mg, week 3, constipation present but not ruining anything. I changed exactly one variable —…
comment on my TSH moved and I cannot work out whether stopped is why in c/darkspot · 5 points · 2 months ago
The thing nobody prepared me for was the quiet. Not the appetite, the quiet. The constant negotiation in my head about food just stopped.
comment on SELECT: the version I wish someone had shown me in week 1 in c/trialwatch · 41 points · 2 months ago
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
comment on genuine question about incretin that I am slightly embarrassed to ask in c/glp1science · 76 points · 2 months ago
Where does the incretin data actually come from?
comment on phase 2 vs triple agonist — genuinely asking which matters more in c/retatrutide · 42 points · 2 months ago
the 0.5mg arm is different from 0.25mg, results do not transfer
comment on 18 months in and TRIUMPH is still the thing I get wrong in c/trialwatch · 2 points · 2 months ago
Strongly agree. Phase 2 is investigational, not conclusive.
comment on [Meta] the Zepbound rule is doing its job and people should stop complaining in c/tirzepatide · 133 points · 2 months ago
This matches the trial data. SURMOUNT-1 was 98.6% body weight at 23 weeks.
comment on fertility is the most under-discussed thing in c/orforglipron in c/glp1women · 6 points · 2 months ago
Crossposting this to c/bpc157 because the people who need it are not reading this community.